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the SLOS membrane has increased 7-DHC and reduced cholesterol content and abnormal membrane
fluidity. X-ray diffraction analyses of synthetic membranes prepared to mimic SLOS membranes revealed
atypical membrane organization. In addition, calcium permeability is markedly augmented, whereas
membrane-bound Na+/K+ATPase activity, folate uptake, inositol-1,4,5-trisphosphate signaling, and cell
proliferation rates are markedly suppressed. These data indicate that the disturbance in membrane sterol
content in SLOS, likely at the level of membrane caveolae, directly contributes to the widespread tissue
abnormalities in this disease.
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A membrane defect in the pathogenesis of the
Smith-Lemli-Opitz syndrome
Thomas N. Tulenko,1,* Kathy Boeze-Battaglia,† R. Preston Mason,§ G. Stephen Tint,**
Robert D. Steiner,†† William E. Connor,§§ and Edward F. Labelle***

Abstract The Smith-Lemli-Opitz syndrome (SLOS) is an
often lethal birth defect resulting from mutations in the
gene responsible for the synthesis of the enzyme 3bhydroxy-steroid-D7-reductase, which catalyzes the reduction
of the double bond at carbon 7 on 7-dehydrocholesterol (7DHC) to form unesterified cholesterol. We hypothesize that
the deficiency in cholesterol biosynthesis and subsequent
accumulation of 7-DHC in the cell membrane leads to defective composition, organization, dynamics, and function
of the cell membrane. Using skin fibroblasts obtained from
SLOS patients, we demonstrate that the SLOS membrane
has increased 7-DHC and reduced cholesterol content and
abnormal membrane fluidity. X-ray diffraction analyses of
synthetic membranes prepared to mimic SLOS membranes
revealed atypical membrane organization. In addition, calcium permeability is markedly augmented, whereas membrane-bound Na+/K+ATPase activity, folate uptake, inositol1,4,5-trisphosphate signaling, and cell proliferation rates are
These data indicate that the
markedly suppressed.
disturbance in membrane sterol content in SLOS, likely at
the level of membrane caveolae, directly contributes to the
widespread tissue abnormalities in this disease.—Tulenko,
T. N., K. Boeze-Battaglia, R. P. Mason, G. S. Tint, R. D.
Steiner, W. E. Connor, and E. F. Labelle. A membrane
defect in the pathogenesis of the Smith-Lemli-Opitz syndrome. J. Lipid Res. 2006. 47: 134–143.
Supplementary key words 7-dehydrocholesterol . 3b-hydroxy-steroidD7-reductase . birth defects . cell membrane . caveolae . rafts

The Smith-Lemli-Opitz syndrome (SLOS) was originally
described in 1964 by three pediatricians, David Smith, Luc
Lemli, and John Opitz (1), who noted the clustering of
a variety of abnormalities and malformations in afflicted

children. Newborns with SLOS have specific facial abnormalities and often suffer from multiple congenital
anomalies, including cleft palate, congenital heart disease,
genitourinary abnormalities, and syndactyly. In addition,
they typically demonstrate mental retardation and brain
abnormalities and are characterized further by an almost
uniform failure to thrive (2, 3). Severity varies in SLOS
patients, but their parents, although heterozygous, are
phenotypically normal. Severity was historically divided
into two phenotypes (4): the more severe clinical phenotype was designated type II and was commonly fatal by
6 months of age, whereas the less severe phenotype was
designated type I and was compatible with survival into
adulthood, albeit with persistence of the clinical features
of SLOS (5). More recently, however, phenotypic variations in SLOS have been thought to reflect a continuum
(6), because patients with different severities have been
shown to have mutations in the same gene (7–9). Based on
clinical criteria, the incidence of SLOS was previously
suggested to range from 1:20,000 to 1:60,000 (10, 11).
However, a more recent study screening for the most
common mutation (IV8-1G.C) calculates the carrier frequency for all mutations at 1 in 30, yielding an incidence
estimate of 1:1,590 to 1:13,500 (12). A similar frequency
was obtained by Nowaczyk et al. (13). By comparison, the
three most common autosomal recessive genetic conditions in childhood are commonly listed as cystic fibrosis
(1:2,500), phenylketonuria (1:14,000), and galactosemia
(1:40,000) (14). Therefore, although not a common disease, SLOS is the second most serious recessive genetic
condition.
Originally, SLOS was defined and diagnosed solely by
clinical criteria. However, Irons, Tint, and colleagues (15,
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Fig. 1. Similarity of molecular structures of 7-dehydrocholesterol
(7-DHC) and cholesterol. Note that the only difference is the
double bond between carbons 7 and 8 in 7-DHC.

naling in a wide variety of cells, and the degree to which
their function is altered by these SLOS sterol alterations
has not been established.
In this study, we used skin fibroblasts obtained from
SLOS patients to evaluate whether membrane sterol composition, organization, and dynamics are abnormal. We
found that membrane lipid dynamics were altered in
SLOS cells. Moreover, they were accompanied by alterations in membrane calcium permeability, Na1/K1ATPase
activity, folate uptake, inositol-1,4,5-trisphosphate (IP3)
signaling, and cell proliferation, suggesting altered membrane function by the SLOS sterol alterations. Together,
these findings demonstrate that in SLOS patients, the
accumulation of 7-DHC, and/or the deficiency in cholesterol biosynthesis, results in cell membranes that are defective and likely contributes to the cellular pathobiology
in SLOS patients.

METHODS
Skin fibroblasts were obtained from patients with SLOS and
healthy control subjects and grown to confluence in MEM 1 10%
FBS supplemented with nonessential amino acids. Before the
experiments, the SLOS cells were transferred to MEM 1 10%
lipoprotein-deficient serum (LPDS) for 5–7 days to remove exposure to exogenous cholesterol (lipoproteins) otherwise present in normal FBS. Fibroblasts from five SLOS patients and five
control subjects were used. The ages of the controls were 2, 2, 7,
9, and 12 years, and the ages of the SLOS patients were 3 months
and 4, 9, 12, and 12 years. All cells were studied between passage
two and eight, and all assays were performed at 37jC. Approval to
use human skin fibroblasts before the initiation of this study was
granted by the University Institutional Review Board.
For membrane sterol measurements, intact microsomes enriched with plasma membranes were isolated as described previously (24, 25). After the addition of 1 mg of coprostanol as an
internal recovery standard, membrane pellets were extracted in
chloroform-methanol (26). The chloroform phase was obtained
and dried under nitrogen. Sterols were identified and quantitated using GC-MS as described previously (16). Briefly, an aliquot
of the extract was hydrolyzed in 1 N NaOH ethanol for 1 h at 70jC,
extracted with n-hexane, and converted into trimethylsilyl ether
derivatives followed by injection into a capillary column. This
column was a chemically bonded, fused silica, nonpolar CP-Sil
5CB (25 m 3 0.25 mm inner diameter; stationary phase, 100%
dimethylsiloxane) (Chrompack, Raritan, NJ), and helium was
used as the carrier gas at a flow rate of 1 ml/min. To achieve
optimal separation of sterols, the column oven temperature was
programmed to change from 100jC to 265jC at 35jC/min after a
2 min delay from the time of injection. The chromatograph was
calibrated with a calibration standard consisting of 1 Ag each of
authentic coprostanol and 7- and 8-DHC (Supelco). Membrane
sterol content is expressed as sterol-protein ratios. Protein determinations were performed using the method of Lowry et al. (27).
For membrane fluidity, steady-state anisotropy (1/membrane fluidity) was measured as described previously (28, 29).
cis-Parinaric acid (CPA) was introduced into membrane vesicles
by incubation of a membrane suspension (5.0 ml) with CPA such
that the final concentration was 0.5 mol% relative to fibroblast
phospholipid for 15 min at 37jC. Fluorescence measurements
were made with excitation at 300 nm and emission at 410 nm
using a Perkin-Elmer LS50B spectrofluorimeter equipped with
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16) were the first to show that increased blood levels of
7-dehydrocholesterol (7-DHC) occurred in SLOS patients,
a finding that ultimately led to the discovery of specific
mutations in the enzyme that catalyzes the biosynthesis
of cholesterol, 3b-hydroxy-steroid-D7-reductase (DHCR7)
(7–9). SLOS is now diagnosed by increased blood levels of
the immediate precursor to cholesterol synthesis, 7-DHC,
coupled with low cholesterol levels. Moreover, the clinical
severity of SLOS has also been shown to correlate with the
levels of blood 7-DHC and cholesterol (17, 18), although
the correlation between sterol levels and clinical severity
is not always strong. Additional evidence supporting a defect in DHCR7 enzyme activity as the biochemical basis
for clinical features of SLOS is found in the early (19) and
more recent work (20) from Roux’s group demonstrating that inhibitors of DHCR7 (AY 9944 and BM 15.766)
produce teratogenic malformations and sterol abnormalities in rats similar to those seen in humans. Xu et al. (21)
have confirmed these findings with BM 15.766, and Honda
et al. (22) have extended these observations to human
skin fibroblasts, in which BM 15.766 inhibited DHCR7
enzyme activity and resulted in the accumulation of 7DHC and the depletion of cholesterol, thereby inducing
SLOS at the cellular level. Because cholesterol is absolutely
required for the biosynthesis of cell membranes, steroids, and sex hormones, the altered sterol synthesis in
SLOS patients may underlie the widespread tissue and
organ malformations.
Because the genetic defect in SLOS leads to a decrease
in cholesterol and a concomitant increase in 7-DHC, it is
reasonable to consider that this sterol imbalance may contribute to SLOS pathogenicity. On first glance, the similarities between cholesterol and 7-DHC appear to dominate
(i.e., they differ by only a double bond between the 7 and
8 carbons in 7-DHC) (Fig. 1). Accordingly, this minor
structural difference may not be biologically relevant. In
fact, an example of this was shown by Cooper et al. (23),
who found that 7-DHC can replace cholesterol in its
activation of the sonic hedge-hog protein (Shh) without
loss of function, suggesting that the pathogenic defect in
SLOS is not at the level of early embryonic segmentation
mediated by Shh. However, the absolute requirement for
cholesterol in the synthesis and function of cell membranes raises the question of whether decreased cholesterol, increased 7-DHC, or their combination might cause
abnormalities in membrane function. Moreover, unique
cholesterol-rich domains (i.e., rafts and caveolae in the cell
membrane) participate in membrane transport and sig-

automatic polarizers. All fluorescence values were corrected for
scattering and background fluorescence by subtraction of the
values obtained from unlabeled membrane suspensions. Steadystate fluorescence anisotropy (rss) was calculated using the modified Perrin equation (30):
r ss 5 IVV 2 GIVH =IVV 1 2GIVH
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where G is calculated as G 5 IHV/IHH and IVH and IHH equal
fluorescence intensities perpendicular and parallel, respectively,
to the excitation plane.
Membrane structure was probed using a small-angle X-ray diffraction technique as described previously (24, 25). This highly
quantitative technique enables the measurement of membrane
structure and organization. Briefly, synthetic membranes were
prepared (25) [cholesterol, 7-DHC, and dimyristoylphosphatidylcholine (PC), 1:1:2] and sedimented by centrifugation (35,000 g
for 1 h at 5jC). On completion of the spin, the pelleted membranes were mounted on a curved glass support such that the
plane of the bilayer was parallel to the incident X-ray beam. X-ray
diffraction was collected using a collimated, monochromatic
copper Ka X-ray source that was focused on the sample at near
grazing incidence in a temperature- and humidity-controlled
brass canister. Diffraction data from the oriented membrane
multilayer samples were recorded on a one-dimensional positionsensitive electronic detector (Innovative Technologies, Inc.,
Newburyport, MA). In addition to direct calibration of the detector system, cholesterol monohydrate was used to verify the calibration. The X-ray reflections collected on film were integrated
using a densitometer, whereas the data from the electron detector were analyzed directly using a standard integration algorithm. One-dimensional electron density profiles generated by
Fourier analysis of the diffraction data were used to characterize
the distribution of the lipid constituents at a resolution of 5–10 Å.
Calcium permeability measurements were made as described
previously (28). Briefly, nearly confluent cells on six-well plates
were equilibrated in PBS for 60 min before experiments were
begun. For assay, PBS was aspirated and replaced with 45Ca21
-PBS (4 ACi/ml), and the cultures were incubated with 45Ca21 for
45 s. 45Ca21 uptake was terminated by placing the dishes on a
26jC frosted cradle, followed by immediate, rapid washing of the
cells with eight washes of 2 ml of ice-cold (0–2jC) PBS (5 s per
wash). Preliminary experiments demonstrated that this wash
protocol removed extracellular 45Ca21 while retaining intracellular 45Ca21 and was equally effective in normal and SLOS cells.
The cells were then lysed with SDS (1 mg/ml), and aliquots of
the lysate were analyzed for protein content and radioactivity.
Calcium uptake was determined from counts derived from the
cell lysate 45Ca21 fraction (cpm) divided by the specific activity of
the 45Ca21-containing uptake medium (cpm/Amol Ca21). The
unidirectional inward flux of calcium was measured by exposing
cells to 45Ca21-PBS for 45 s and is expressed as nanomoles of Ca
uptake per milligram of protein per minute. Preliminary experiments demonstrated that his incubation time falls within the
linear portion of the calcium uptake curve.
Steady-state Na1/K1ATPase activity in control and SLOS
fibroblasts grown to confluence was measured as described previously (31) with modifications for cultured cells. Activity was
assessed using a 20 min pulse of the kaliometic isotope 86Rb
(1 ACi/ml) in the presence and absence of ouabain (3 mM),
followed by rapid washing with PBS. The cells were digested in
1% SDS, and the digest was counted for radioactivity using a
liquid scintillation counter. Ouabain-insensitive 86Rb uptake was
subtracted from total 86Rb uptake to obtain ouabain-sensitive
Na1/K1ATPase activity, which is expressed as nanomoles of Rb
per milligram of cell protein per minute.

For folate uptake measurements, uptake of the reduced folate
derivative 5-methyltetrahydrofolate into the cytosol of fibroblasts
was quantitated using the method described by Stevens and Tang
(32). Briefly, cells were incubated with 5 nM 5-[3H]methyltetrahydrofolate (0.5 ACi) in folate-free medium for 15, 30, 45, and
60 min at 37jC. The medium was removed and the cells were
washed four times with PBS followed by the addition of 1.5 ml
of lysis buffer (10 mM Tris-HCl, pH 8.0, 20 Ag/ml leupeptin,
20 Ag/ml aprotinin, and 1 AM 5-methyltetrahydrofolate) to each
well. The cells were then lysed by placing the culture plates
at 280jC for at least 15 min and thawed on ice. The cells were
collected and centrifuged for 20 min at 100,000 g in a Beckman
ultracentrifuge to separate the membrane pellet from the cytosolic (supernatant) fractions. The radioactivity in each fraction
was quantitated by scintillation counting. Nonspecific uptake was
measured using 2.5 AM 5-[3H]methyltetrahydrofolate and subtracted from the total radioactivity to give the specific uptake.
The results were normalized to total cell protein determined
using the method of Lowry et al. (27).
Inositol phosphate (IP) production in SLOS fibroblasts was
determined by the procedure of Carney et al. (33). Confluent
monolayers of SLOS fibroblasts were prepared in T75 culture
flasks, and [3H]inositol (2 ACi/ml) was added to each flask and
allowed to incubate for 36 h. The reaction was stopped by rinsing
the plates in ice-cold phosphate-buffered saline and adding 2 ml
of trichloroacetic acid (10%) to each plate. After 5 min, the TCA
was removed and the plate was rinsed with an additional 2 ml of
TCA. The combined TCA washes were extracted five times with
ethyl ether to remove the TCA, and the aqueous phase was applied to 1 ml Dowex (1 3 8–50 resin formate form, 200–400 mesh)
columns. The columns were eluted with water to remove free
inositol, followed by 0.1 M formic acid containing 0.2 M ammonium formate to remove [3H]inositol-4-phosphate (IP1), 0.4 M
ammonium formate to remove [3H]inositol-1,4-bisphosphate
(IP2), and 1 M ammonium formate to remove [3H]IP3. The radioactivity of each fraction was determined by liquid scintillation
counting. Total IPs were derived by adding the counts from the
IP1, IP2, and IP3 fractions.
Cell proliferation was assessed by measuring [3H]thymidine
uptake into DNA as described previously (34). Cells were grown
to near confluence and incubated overnight with [3H]thymidine.
The cells were then rinsed with PBS followed by extraction and
rinsing five times with 10% TCA. The TCA-precipitable material
was dissolved overnight with 0.5 ml of KOH (0.5 M) at 23jC,
followed by treatment with 0.25 ml of HCl (1 M) before being
transferred to scintillation vials (10 ml volume), and the radioactivity was determined by liquid scintillation counting.
Enrichment of the SLOS cell membranes with cholesterol was
accomplished using cholesterol-rich liposomes as described previously (28, 34). Cholesterol-rich liposomes were prepared by
cosonication of cholesterol with egg phosphatidylcholine in a 2:1
molar ratio, followed by centrifugation, filter sterilization, and
confirmation by gas-liquid chromatography and phospholipidphosphorus colorimetry before experimentation. Cell monolayers were incubated with cholesterol-donor liposomes (250 Ag
liposomal cholesterol/ml) and incubated for 24 h at 37jC. At the
end of the incubation, the cells were washed with PBS containing
0.1% BSA to remove any adherent liposomal particles from the
cell surface membranes. Wells from each experiment were assayed for cholesterol content to verify enrichment.
In all experiments, n equals the number of patients studied,
and the data are expressed as the mean 6 SEM. In most experiments, statistical analysis was performed on paired and unpaired
data by use of Students t-test or repeated-measures ANOVA.
Multiple comparisons were analyzed using the Newman-Keuls
test. Statistical significance was taken as P , 0.05.

RESULTS

Fig. 2. Sterol composition of normal (left) and Smith-Lemli-Opitz
syndrome (SLOS; right) cell membranes. Cells were grown to near
confluence in MEM 1 10% FBS, followed by incubation in MEM 1
10% lipoprotein-deficient serum for 7–10 days (n 5 5 subject cell
lines/group). Error bars represent mean 6 SEM.
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SLOS fibroblasts grown in medium containing 10% FBS
show normal cholesterol and modest 7-DHC content
(28.0 6 7.43 and 1.07 6 0.44 Ag/mg protein, respectively)
compared with cells maintained on delipidated serum
(10% LPDS) for up to 1 week (32.36 6 1.47 and 7.13 6
1.46 Ag/mg protein, respectively). These values of cholesterol and 7-DHC in SLOS cells are in close agreement
with those reported by Wassif et al. (9) in SLOS fibroblast
also grown in LPDS. LPDS removes the source of exogenous cholesterol (from lipoprotein) and results in the
development of membrane sterol profiles typical of SLOS
(Fig. 2). Because normal activity of DHCR7 is present in
control cells, the primary sterol typically found in normal
fibroblasts is cholesterol, with only negligible levels of
7-DHC. The presence of accumulated 7-DHC and reduced
levels of cholesterol in their membranes confirms impaired DHCR7 activity in the SLOS cells in this study.
Although 8-DHC is also present in the blood of SLOS
patients, its conversion from 7-DHC occurs primarily in
the liver (35). For this reason, increased 8-DHC levels
would not be expected in fibroblasts serially passed in culture. The low 8-DHC levels (0.33 6 0.03 Ag/mg protein)
detected in the SLOS cells likely reflect a small degree of
cellular conversion of 7-DHC to 8-DHC. That impaired
DHCR7 is the sole reason for the appearance of DHCs in
SLOS fibroblasts is supported by the observation that the
total sterol content in the SLOS membrane is not significantly different between control and SLOS cells. It is important to note, however, that measurements in cultured
cells may not be in complete agreement with similar assessments made in vivo, but because of limitations in obtaining enough freshly purified fibroblasts from young
children, in vivo studies were not possible in this study.

To assess the physical state of the cell membrane in
SLOS cells, we used two independent experimental
strategies. In the first, we assessed membrane fluidity by
measuring fluorescence anisotropy, a property inversely
related to membrane fluidity. The fluorophore used in
this study was CPA, a fluorescent sterol probe that reports
on fluidity in the hydrocarbon core (fatty acyl chain
region) of the membrane (36). As illustrated in Fig. 3A,
anisotropy was reduced in the membranes isolated from
SLOS cells, reflecting a significant increase (z20%) in
membrane fluidity in the fatty acyl region of the membrane. Supporting this finding was a decrease in electron
density in this region observed using the second strategy,
small-angle X-ray diffraction (Fig. 3B). In this experiment,
diffraction was obtained using synthetic membranes prepared to resemble the SLOS membrane (i.e., z25% of the

Fig. 3. A: Increased membrane fluidity (decreased anisotropy) in
plasma membranes of SLOS fibroblasts. The probe used in this
study was cis-parinaric acid. * P , 0.05; n 5 5 subject cell lines/
group. B: X-ray diffraction analysis in model membranes prepared
with sterol-phospholipid ratios observed in control fibroblasts
(solid line) and SLOS fibroblasts (broken line). Note the increase
in electron density seen at the membrane surface and the
decreased electron density seen in the hydrocarbon core region
in the SLOS versus control membranes, reflecting an increase and
decrease, respectively, in phospholipid packing in these regions. A
model phospholipid bilayer is shown at the top of the electron
density profile for orientation. Error bars represent mean 6 SEM.
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Fig. 4. Increase (three times) in calcium permeability in SLOS
versus control fibroblasts. Cholesterol enrichment restores calcium
permeability toward control levels in SLOS fibroblasts. The data
represent triplicate measures in cell lines from each of three control subjects and three SLOS subjects. * P , 0.01, versus control.
Error bars represent mean 6 SEM.

138

Journal of Lipid Research

Volume 47, 2006

Fig. 5. Steady-state Na1/K1ATPase in control and SLOS fibroblasts. Cholesterol enrichment restores Na1/K1ATPase activity
toward control levels in SLOS fibroblasts. The data represent triplicate measures in cell lines from each of three control subjects and
three SLOS patients. * P , 0.001, SLOS versus control; † P , 0.01,
SLOS 1 cholesterol versus SLOS. Error bars represent mean 6 SEM.

and SLOS fibroblasts. A decrease of z50% was observed
among all the IPs: IP1, IP2, IP3, and total IPs (Fig. 7A). The
reduction was statistically significant among all of the IPs
with the exception of IP3, which approached (P= 0.06) but
did not reach statistical significance. The reduction in IPs
in SLOS cells does not reflect a reduction in the cellular
inositol lipid pools, because labeling to isotopic equilibrium demonstrated equivalent labeling in both control
and SLOS cells (Fig. 7B). These data reflect general impairment in membrane-mediated cell signaling through
the IP pathway in SLOS cells.

Fig. 6. Reduced folate uptake in SLOS fibroblasts compared with
control fibroblasts. The data represent triplicate measurements
from two SLOS patients and two control subjects. * P , 0.01. Error
bars represent mean 6 SEM.
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total lipid was 7-DHC). Thus, both approaches to assess
the membrane physical state indicate reduced molecular
packing in the fatty acyl chain region of the membrane
bilayer. Interestingly, the electron density at the surface of
the membrane obtained from the X-ray data appeared to
be increased, reflecting an increase in molecular packing
at the surface of the membrane.
Having established that the physical state of the membrane is disturbed in SLOS cells, we then assessed membrane functional properties. Using 45Ca, unidirectional
calcium uptake was observed to be increased by 3-fold in
SLOS cells compared with control cells (Fig. 4). Adding
cholesterol back to the cells decreased calcium permeability approximately halfway back toward control levels.
Using the kaliometic isotope 86Rb1 to follow K1, we observed a marked decrease in ouabain-sensitive Rb uptake
in the SLOS cells (Fig. 5). This technique has been shown
by us and others to directly measure membrane-bound
Na/K ATPase activity (31, 37). Like calcium permeability,
Na/K ATPase activity also returned about halfway toward
control levels after enrichment with exogenous cholesterol. Enrichment of the SLOS cells with cholesterol increased cholesterol content by 42.4% (29.5 6 5 vs. 42.0 6
7 Ag/mg protein), with no change in 7-DHC content.
A significant anatomic malformation found in many
SLOS patients is cleft palate. Because cleft palate has been
established to result, in part, from folate deficiency, we
assessed folate uptake in the SLOS cells. As illustrated in
Fig. 6, folate uptake, using a [3H]methyltetrahydrofolate
protocol, was suppressed by z50% in the SLOS cells.
Cell signaling by IP occurs by enzymatic cleavage of
inositol from membrane-resident phosphatidylinositol. To
determine whether membrane-mediated IP signaling is
altered in SLOS, we measured IP production in control

Fig. 7. A: Reduced inositol phosphate (IP), inositol-1,4bisphosphate (IP2), inositol-1,4,5-trisphosphate (IP3), and
total IP generation and its recovery after cholesterol enrichment in SLOS fibroblasts compared with normal fibroblasts. B: Control and SLOS cells were incubated with
[3H]inositol (10 ACi/ml) for 24 h followed by lipid extraction and counting of radioactivity by liquid scintillation.
The data represent triplicate measures in cell lines from
four SLOS patients and five control subjects. * P , 0.05.
Error bars represent mean 6 SEM.

DISCUSSION
The elucidation of an inherited defect in DHCR7
enzyme activity as the biochemical abnormality underlying

Fig. 8. Reduced cell proliferation in SLOS fibroblasts. Cells were
plated on six-well plates, grown to near confluence, and incubated
overnight with [3H]thymidine (3H-TdR). Radioactivity was measured in the TCA-insoluble (DNA) fraction. The data represent
triplicate measures in fibroblasts from five SLOS patients and five
control subjects. * P , 0.01. Error bars represent mean 6 SEM.

SLOS by Irons, Tint, and colleagues (15, 16) has led to the
identification of the molecular basis of the SLOS syndrome. Molecular cloning of the human DHCR7 cDNA
by Moebius et al. (38) demonstrated that DHCR7 is a
membrane-bound protein with a molecular mass of 55 kDa
with six to nine transmembrane domains. Chromosomal
mapping localized the gene to chromosome 11q12-13. A
variety of mutations in the DHCR7 gene have been reported in patients with SLOS, including missense, nonsense, frame shift, and splice site mutations (7–9, 38), and
all are associated with reduced blood and tissue cholesterol levels with increases in 7-DHC. Moreover, regardless
of the nature of the mutation, the degree of cholesterol
synthesis by the mutant DHCR7 determines the ratio of
cholesterol to 7-DHC, which is somewhat predictive of the
severity of the disease (18).
Although the genetic basis of SLOS and the resulting
depletion of cholesterol and accumulation of 7-DHC
in tissues have been demonstrated, the cellular defects
associated with SLOS have not been well described. Accordingly, we analyzed a variety of membrane functions
in fibroblasts obtained from SLOS patients to test the hypothesis that a defect exists in the lipid bilayer of SLOS
cells that alters the membrane in ways that interfere with
the function of various membrane proteins, and thus also
cell and tissue function, in this disease. We surmise that
such a defect would be caused by the presence of 7-DHC,
reduction in cholesterol, or a combination of the two.
That the cell’s plasma membrane is altered in this disease
is confirmed on the basis of a relative depletion of cholesterol (27.8%) and a massive accumulation of 7-DHC
(z264-fold) in the membranes of fibroblasts isolated from
SLOS patients (Fig. 2). As anticipated, 7-DHC content was
exceedingly low (0.027 6 0.009 Ag/mg protein) in membranes isolated from fibroblasts obtained from normal
subjects. Interestingly, the total sterol content of SLOS
membranes was not significantly different from that
of normal membranes. Despite their similar total sterol
content, membrane fluidity was increased significantly
Membrane defect in SLOS
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Finally, during the daily care and feeding of the SLOS
cells, it became clear that the SLOS cells were growing
more slowly than the control cells. For this reason, we
measured cell proliferation rates using a [3H]thymidine
uptake protocol. As shown in Fig. 8, SLOS fibroblasts
incorporated thymidine at less than half the rate seen in
control fibroblasts, reflecting a reduced rate of cell proliferation. Reduced cell proliferation was confirmed in some
experiments by direct cell counting (data not shown).
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membrane may lead to intracellular folate deficiency and
thereby contribute to the common appearance of cleft
palate in SLOS. The precise location of the folate uptake
pathway in the plasma membrane has not been established, but recent studies localize it to cholesterol-rich
membrane domains of either the caveolar (42) or noncaveolar (43) lipid raft types.
The final membrane-mediated activity we investigated
was the generation of signaling IPs. These second messengers, particularly IP3, are involved in regulating intracellular calcium levels in response to a variety of extracellular
stimuli. We observed essentially uniform reductions in IP1,
IP2, IP3, and total IP levels in SLOS cells compared with
control cells. This impairment in IP signaling raises the
question of impaired cell signaling by the IP pathway. One
of the important cell functions regulated by IP signaling
is cell calcium modulation and its control over cell proliferation (44, 45). As shown in Fig. 8, cell proliferation,
based on [3H]thymidine incorporation into cellular DNA,
is significantly suppressed in SLOS cells compared with
control cells. Although the cellular basis for this effect cannot be established from our data, its suppression in SLOS
cells is consistent with impaired IP3 signaling. The relevance of these observations to SLOS may be important
because SLOS patients almost uniformly demonstrate a
failure to grow normally, and a generalized impairment
in cell proliferation may contribute to impaired somatic
growth and/or development.
Relevant to our findings are those reported by Wassif
et al. (46), who created a DHCR7 null mouse model of
SLOS that has many of the same malformations and neurologic abnormalities seen in human SLOS. They demonstrated marked impairment of glutamate-activated Na1
currents in cortical neurons from these animals. Importantly, this impaired activity did not appear to be caused
by alterations in glutamate receptor subunit mRNA expression determined by RT-PCR, consistent with our proposal that the cell membrane may be altered in SLOS
in ways that interfere with receptor activity. Interestingly,
these same experiments failed to show differences in
voltage-activated, tetrodotoxin-sensitive, org-aminobutyrateactivated Na1 currents between control and SLOS animals,
indicating a selective effect of SLOS on glutamate receptormediated activity.
The current study focuses specifically on the potential
for abnormal sterol composition of the cell membrane to
induce a generalized membrane defect in SLOS. We show
that two specific membrane-mediated abnormalities, cell
calcium permeability and Na1/K1ATPase activity, occur
in SLOS fibroblasts. Because restoring membrane cholesterol content without altering the 7-DHC accumulation in
SLOS cells resulted in only partial restoration of activity,
we postulate that the defect is not mediated by a reduction
in membrane cholesterol content alone but rather by the
combination of reduced cholesterol plus the accumulation of 7-DHC in the membrane. Although we report
on plasma membrane structure/function in this study, it
should be noted that similar alterations may occur in intracellular membranes as well (e.g., endoplasmic reticulum,
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(z20%) in membranes isolated from SLOS patients
(Fig. 3A). The fluorophore used to evaluate fluidity,
CPA, reports on molecular packing in the center (i.e., the
fatty acyl chain region of the membrane). This observation
is confirmed in X-ray diffraction data obtained from
model membranes prepared from cholesterol, 7-DHC,
and PC to mimic the SLOS membrane. As shown in Fig.
3B, the relative electron density is decreased in the fatty
acyl chain region of the membrane, confirming the decreased intermolecular packing of phospholipid fatty acyl
chains suggested by the fluorescence anisotropy data. This
decrease in acyl chain packing is associated with a reciprocal increase in molecular packing at the surface of the
membrane. A reciprocal relationship between core and
surface molecular packing density of the membrane has
been established by others as a typical feature in a variety
of membranes (39, 40). These data using two separate,
different, and independent methods to assess molecular
packing in the membrane (i.e., fluidity and X-ray diffraction) clearly demonstrate that the apparently minor differences between cholesterol and 7-DHC structure confer
significant differences in membrane lipid organization
and dynamics. Although tissue sterols in SLOS have been
reported (22), this is the first report of membrane sterol
composition, dynamics, and organization in this disease.
To determine whether these are associated with alterations in membrane function, we assessed two key membrane properties that have been widely established as
fundamentally important to cell biology across the phylogenetic spectrum: membrane calcium permeability and
membrane-bound Na1/K1ATPase activity. As shown in
Fig. 4, calcium permeability is increased by 3-fold in SLOS
fibroblasts compared with controls. The identity of this
altered calcium entry pathway cannot be determined
from our data, but it likely involves either nonselective or
selective ion channels (i.e., voltage-gated, receptor-gated,
capacitative calcium entry channels, etc.). Interestingly,
after cholesterol enrichment, the augmented calcium permeability in SLOS cells declined by z50%, suggesting
partial restoration of the calcium influx pathway. A similar
observation was obtained by measuring Na1/K1ATPase
activity, which was markedly reduced in SLOS cells compared with control cells (Fig. 5). Moreover, like calcium
permeability, partial restoration of membrane Na1/
K1ATPase activity was observed in SLOS cells after cholesterol enrichment. That these data reflect membrane
function specifically at the cell’s plasma membrane is
implied because the measurements were made using ion
translocation (45Ca21 and 86Rb, extracellular to intracellular) in cell monolayers as well as the activity of a protein
asymmetrically distributed to the cell surface membrane
(Na1/K1ATPase).
Another plasma membrane protein whose activity we
assessed is the folate transport protein. Folate uptake into
SLOS cells was depressed by z50% compared with control
cells. Because cleft palate is well known to result, in part,
from folate deficiency in the general population, and cleft
palate malformations occur in 40–50% of SLOS children
(41), we suggest that impaired folate uptake across the cell

processing (23). The second role for cholesterol is in
steroidogenesis, and a number of investigators have shown
abnormal steroids in SLOS children that likely contribute
to the SLOS phenotype (57). Third, cholesterol is essential
for the synthesis of cell membranes, and it is the only sterol
that mammals normally use in this capacity. In the membrane, it sets the levels of membrane fluidity, permeability,
and, importantly, membrane width (24, 25, 34) appropriate for the specific membrane type (for width, plasma
membrane . endoplasmic reticulum z Golgi . mitochondrial, etc.) (58). We show that 7-DHC cannot substitute for cholesterol in the membrane because it alters
phospholipid packing and thus also membrane lipid dynamics. Because SLOS typically shows widespread organ
dysfunction, we propose that the disturbance in sterol synthesis, namely the decrease in cholesterol content combined with the accumulation of 7-DHC in the membrane,
accounts for the widespread abnormalities that occur in
multiple organs in patients afflicted with SLOS. We further propose that membrane caveolae are particularly affected in SLOS by the abnormal sterol complement,
resulting in defective cellular signaling cascades.
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